{"id":7509,"date":"2019-07-23T00:00:00","date_gmt":"2019-07-22T22:00:00","guid":{"rendered":"https:\/\/irb.usi.ch\/uncategorized\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/"},"modified":"2020-06-23T16:51:02","modified_gmt":"2020-06-23T14:51:02","slug":"gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325","status":"publish","type":"post","link":"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/","title":{"rendered":"Gain Therapeutics SA Announces Award Notification of a \u20ac1.4M Grant Support from Eurostars-2 together with the Institute for Research in Biomedicine and Neuro-Sys SAS after having scored 2nd among 325 Eligible Applications"},"content":{"rendered":"<p class=\"news-publication\"><span>on<\/span> <span class=\"date-display-single\">July 23, 2019<\/span><\/p>\n<p class=\"rtejustify\">Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Universit\u00e0 della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse \u2013 Swiss Innovation Agency.<\/p>\n<p class=\"rtejustify\">This grant will further strengthen Gain Therapeutics\u2019s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and\/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the treatment of Gaucher Disease, GM1 Gangliosidosis and Parkinson\u2019s Disease.<\/p>\n<p class=\"rtejustify\">\u201cWe are proud of the Eurostars-2 grant notification, where Gain Therapeutics\u2019 platform technology for identifying structurally targeted allosteric regulators has been very positively evaluated due to:&nbsp; clear unmet medical needs (and namely orphan, rare and defined diseases with a strong neurological need still unmet);&nbsp; novel platform technology developing brain penetrant small molecules able to restore misfolded lysosomal enzyme; a clearly defined path into a significant market; a balanced yet ambitious project with a strong IP estate,\u201d said Dr. Manolo Bellotto, General Manager of Gain Therapeutics SA.<\/p>\n<p class=\"rtejustify\">\u201cThe excellent ranking of our consortium as 2<sup>nd<\/sup> best among over 325 eligible consortia from all over Europe is also a rewarding recognition for our long-standing activity in the field of rare diseases. The transnational collaboration with Gain Therapeutics and Neuro-Sys will hopefully offer the opportunity to translate into the clinics, the research activity performed at the IRB and aiming at understanding how perturbations in protein folding may cause severe diseases\u201d said Dr. Maurizio Molinari, Group leader at the IRB, Bellinzona and Adjunct Professor at the \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne (EPFL).<\/p>\n<p class=\"rtejustify\">\u201cThe innovative scientific approach of the project has strongly motivated us to get involved. The remarkable ranking at European level clearly demonstrates Europe&#8217;s interest in developing innovative cures for orphan indications. The collaboration with Gain Therapeutics and IRB on this ambitious project is a great opportunity to develop innovative platforms and to get a better understanding of the mechanisms of these rare diseases.\u201d said Dr. Noelle Callizot, CSO and General Manager of Neuro-Sys SAS.<\/p>\n<p class=\"rtejustify\">&nbsp;<\/p>\n<p class=\"rtejustify\">About Gain Therapeutics SA<\/p>\n<p class=\"rtejustify\">Gain Therapeutics SA is a Swiss biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform \u2013 SEE-Tx. <a href=\"https:\/\/www.gaintherapeutics.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.gaintherapeutics.com\/<\/a><\/p>\n<p class=\"rtejustify\">About Institute for Research in Biomedicine<\/p>\n<p class=\"rtejustify\">Founded in 2000 in Bellinzona, the IRB is affiliated with the Universit\u00e0 della Svizzera italiana, since 2010. IRB hosts 13 research groups studying defense mechanisms to fight infections, tumors and degenerative diseases. With more than 630 publications in main scientific journals, the IRB has gained international recognition as a center of excellence for immunology and cell biology. Molinari\u2019s laboratory investigates the protein quality control processes determining whether a polypeptide should be secreted, retained in the ER, or selected for degradation. Particular emphasis is given to the study of select rare diseases such as \u03b11-antitrypsin deficiency, LSDs and Charcot-Marie-Tooth 1B neuropathy. <a href=\"https:\/\/irb.usi.ch\" target=\"_blank\" rel=\"noopener noreferrer\">www.irb.usi.ch<\/a>&nbsp;<\/p>\n<p class=\"rtejustify\">About Neuro-Sys<\/p>\n<p class=\"rtejustify\">Neuro-Sys is expert in preclinical in vitro models of neurodegenerative and neurological diseases. It has developed specific models to accurately determine the pharmacological profiling of lead compounds and explore their underlying mechanism of action and to determine the therapeutic indication. With a great team of experts in pharmacology and drug development and an innovative proprietary automated medium throughput platform combined with advanced models, it provides predictable results and a unique approach in the neurodegenerative diseases research. The company\u2019s many loyal pharma and biotech customers around the world are the best testimony to the efficiency and reliability of its solution. <a href=\"http:\/\/www.neuro-sys.com\" target=\"_blank\" rel=\"noopener noreferrer\">www.neuro-sys.com<\/a><\/p>\n<p><img alt=\"\" src=\"\/images\/image_pr_mmo_july2019.jpg\" style=\"width: 700px; height: 396px;\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>on July 23, 2019 Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Universit\u00e0 della Svizzera [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[16],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v15.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gain Therapeutics SA Announces Award Notification of a \u20ac1.4M Grant Support from Eurostars-2 together with the Institute for Research in Biomedicine and Neuro-Sys SAS after having scored 2nd among 325 Eligible Applications - IRB USI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gain Therapeutics SA Announces Award Notification of a \u20ac1.4M Grant Support from Eurostars-2 together with the Institute for Research in Biomedicine and Neuro-Sys SAS after having scored 2nd among 325 Eligible Applications - IRB USI\" \/>\n<meta property=\"og:description\" content=\"on July 23, 2019 Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Universit\u00e0 della Svizzera [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/\" \/>\n<meta property=\"og:site_name\" content=\"IRB USI\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-22T22:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-23T14:51:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/irb.usi.ch\/images\/image_pr_mmo_july2019.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\">\n\t<meta name=\"twitter:data1\" content=\"3 minuti\">\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irb.usi.ch\/it\/#website\",\"url\":\"https:\/\/irb.usi.ch\/it\/\",\"name\":\"IRB USI\",\"description\":\"Institute for Research in Biomedicine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/irb.usi.ch\/it\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"it-IT\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/#primaryimage\",\"inLanguage\":\"it-IT\",\"url\":\"\/images\/image_pr_mmo_july2019.jpg\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/#webpage\",\"url\":\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/\",\"name\":\"Gain Therapeutics SA Announces Award Notification of a \\u20ac1.4M Grant Support from Eurostars-2 together with the Institute for Research in Biomedicine and Neuro-Sys SAS after having scored 2nd among 325 Eligible Applications - IRB USI\",\"isPartOf\":{\"@id\":\"https:\/\/irb.usi.ch\/it\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/#primaryimage\"},\"datePublished\":\"2019-07-22T22:00:00+00:00\",\"dateModified\":\"2020-06-23T14:51:02+00:00\",\"author\":{\"@id\":\"https:\/\/irb.usi.ch\/it\/#\/schema\/person\/c9b66c69925e1b0c558072acbadf4156\"},\"breadcrumb\":{\"@id\":\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/it\/\",\"url\":\"https:\/\/irb.usi.ch\/it\/\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"position\":2,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/.\/news\/\",\"url\":\"https:\/\/irb.usi.ch\/.\/news\/\",\"name\":\"News\"}},{\"@type\":\"ListItem\",\"position\":3,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/\",\"url\":\"https:\/\/irb.usi.ch\/it\/news\/gain-therapeutics-sa-announces-award-notification-of-a-e1-4m-grant-support-from-eurostars-2-together-with-the-institute-for-research-in-biomedicine-and-neuro-sys-sas-after-having-scored-2nd-among-325\/\",\"name\":\"Gain Therapeutics SA Announces Award Notification of a \\u20ac1.4M Grant Support from Eurostars-2 together with the Institute for Research in Biomedicine and Neuro-Sys SAS after having scored 2nd among 325 Eligible Applications\"}}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/irb.usi.ch\/it\/#\/schema\/person\/c9b66c69925e1b0c558072acbadf4156\",\"name\":\"AD_Dave\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/posts\/7509"}],"collection":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/comments?post=7509"}],"version-history":[{"count":0,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/posts\/7509\/revisions"}],"wp:attachment":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/media?parent=7509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/categories?post=7509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/tags?post=7509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}